Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

New research into GLP-1 receptor has opened a realm of new treatment possibilities to treat opioid use disorder (OUD), a ...

PASADENA, CA, USA I February 25, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

Terns announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...